

Ciro Franzese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/906184/publications.pdf>

Version: 2024-02-01

122
papers

2,247
citations

218381

26
h-index

288905

40
g-index

123
all docs

123
docs citations

123
times ranked

3525
citing authors

#	ARTICLE	IF	CITATIONS
1	Discrepancies between UICC and AJCC TNM classifications for oral cavity tumors in the 8th editions and following versions. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 527-531.	0.8	4
2	Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of ARO's Head and Neck working group. <i>Oral Diseases</i> , 2022, 28, 345-351.	1.5	7
3	Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study. <i>Radiotherapy and Oncology</i> , 2022, 167, 89-96.	0.3	13
4	Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 710-718.	1.0	5
5	Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2022, 61, 553-559.	0.8	2
6	Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 449-457.	1.7	5
7	Stereotactic radiotherapy for liver oligometastases. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 32-39.	0.3	2
8	Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 133-140.	1.0	6
9	Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 396-404.	1.0	8
10	Accuracy of fine needle aspiration cytology in detecting cervical node metastasis after radiotherapy: Systematic review and meta-analysis. <i>Head and Neck</i> , 2021, 43, 987-996.	0.9	2
11	The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. <i>Radiotherapy and Oncology</i> , 2021, 156, 49-55.	0.3	2
12	Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 927-936.	1.2	9
13	Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1307-1313.	1.2	24
14	Dosimetric impact of volumetric modulated arc therapy for nasopharyngeal cancer treatment. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 101-110.	0.3	3
15	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. <i>Medical Oncology</i> , 2021, 38, 72.	1.2	6
16	Critical Re-Evaluation of a Failure Mode Effect Analysis in a Radiation Therapy Department After 10 Years. <i>Practical Radiation Oncology</i> , 2021, 11, e329-e338.	1.1	4
17	Radiotherapy role in non-seminomatous germ cell tumors, radiobiological and technical issues of an unexplored scenario. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1777-1783.	1.0	1
18	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. <i>Cancer Treatment Reviews</i> , 2021, 98, 102206.	3.4	30

#	ARTICLE	IF	CITATIONS
19	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7009-7031.	0.9	0
20	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3619-3625.	1.2	5
21	Response to letter to the editor regarding C Franzese et al. "Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer". <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	0
22	Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 511-518.	1.7	9
23	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 T</i> 2021, 38, 527-537.	1.7	14
24	Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients. <i>Laryngoscope</i> , 2020, 130, E163-E170.	1.1	11
25	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 213-221.	1.0	29
26	Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience. <i>Clinical Lung Cancer</i> , 2020, 21, 86-93.	1.1	4
27	Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 325-333.	1.0	19
28	A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 922-931.	1.0	12
29	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. <i>British Journal of Radiology</i> , 2020, 93, 20190627.	1.0	11
30	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent. <i>Lung Cancer</i> , 2020, 141, 1-8.	0.9	17
31	Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 628-635.	0.6	6
32	The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382098041.	0.8	2
33	Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 480-486.	1.1	10
34	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2289-2297.	1.2	12
35	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 565-573.	1.7	9
36	Present and Future of De-intensification Strategies in the Treatment of Oropharyngeal Carcinoma. <i>Current Oncology Reports</i> , 2020, 22, 91.	1.8	25

#	ARTICLE	IF	CITATIONS
37	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?. Radiotherapy and Oncology, 2020, 150, 184-190.	0.3	12
38	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. Critical Reviews in Oncology/Hematology, 2020, 148, 102894.	2.0	27
39	The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality. Frontiers in Oncology, 2020, 10, 7.	1.3	30
40	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1227-1234.	1.2	5
41	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiation Oncology, 2020, 15, 12.	1.2	14
42	Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 608-616.	1.0	8
43	Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 885.	1.7	10
44	Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis. Tumori, 2019, 105, 47-54.	0.6	11
45	Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiotherapy and Oncology, 2019, 139, 83-86.	0.3	40
46	Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. British Journal of Radiology, 2019, 92, 20190252.	1.0	8
47	RapidPlan knowledge based planning: iterative learning process and model ability to steer planning strategies. Radiation Oncology, 2019, 14, 187.	1.2	39
48	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2469-2479.	1.2	14
49	Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1095-1105.	0.4	15
50	A Multi-Institutional Analysis on the Use of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Lymph Node Oligometastases in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2019, 105, E298.	0.4	0
51	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS ONE, 2019, 14, e0210758.	1.1	58
52	Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics. Strahlentherapie Und Onkologie, 2019, 195, 805-818.	1.0	36
53	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	1.2	69
54	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. British Journal of Radiology, 2019, 92, 20190021.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 614-621.	0.4	22
56	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 111-121.	0.4	30
57	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 133, 220-226.	0.3	49
58	Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 163-170.	2.0	26
59	Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2019, 201, 70-76.	0.2	44
60	Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases. <i>World Journal of Surgery</i> , 2018, 42, 2651-2659.	0.8	27
61	Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 108-113.	0.3	15
62	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1507-1513.	1.2	35
63	Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. <i>Radiation Oncology</i> , 2018, 13, 234.	1.2	73
64	Critical Appraisal of the Treatment Planning Performance of Volumetric Modulated Arc Therapy by Means of a Dual Layer Stacked Multileaf Collimator for Head and Neck, Breast, and Prostate. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880388.	0.8	26
65	Randomized Phase III Trial Comparing Gamma Knife and Linac Based (EDGE) Approaches for Brain Metastases Radiosurgery: Results from the Gadget Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S143-S144.	0.4	9
66	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. <i>Radiation Oncology</i> , 2018, 13, 166.	1.2	27
67	Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 951-956.	0.5	8
68	Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1777-1783.	1.2	28
69	The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. <i>Cancer Medicine</i> , 2018, 7, 4379-4386.	1.3	29
70	Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. <i>Breast</i> , 2018, 42, 31-37.	0.9	14
71	Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0201992.	1.1	8
72	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 295-301.	0.8	80

#	ARTICLE	IF	CITATIONS
73	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Reports of Practical Oncology and Radiotherapy, 2017, 22, 163-169.	0.3	14
74	Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after RO surgery: A retrospective study. European Journal of Surgical Oncology, 2017, 43, 735-742.	0.5	33
75	Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1301-1309.	1.2	14
76	Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer. Strahlentherapie Und Onkologie, 2017, 193, 385-391.	1.0	7
77	Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. British Journal of Radiology, 2017, 90, 20170022.	1.0	5
78	RapidPlan head and neck model: the objectives and possible clinical benefit. Radiation Oncology, 2017, 12, 73.	1.2	66
79	P2.05-008 Can Stereotactic Body Radiation Therapy (SBRT) Be an Effective Treatment for Lung Metastases From "Radioresistant" Histologies?. Journal of Thoracic Oncology, 2017, 12, S1035.	0.5	0
80	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1293-1299.	1.2	26
81	11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. Cancer Investigation, 2017, 35, 586-593.	0.6	14
82	Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. British Journal of Radiology, 2017, 90, 20170422.	1.0	13
83	EP-1343: Is stereotactic body radiation therapy a viable option for elderly patients with prostate cancer?. Radiotherapy and Oncology, 2017, 123, S720-S721.	0.3	0
84	EP-1409: Prospective study of hypofractionated radiotherapy for elderly patients with High Grade Glioma. Radiotherapy and Oncology, 2017, 123, S753-S754.	0.3	0
85	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. British Journal of Radiology, 2017, 90, 20170257.	1.0	14
86	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. World Neurosurgery, 2017, 105, 184-190.	0.7	13
87	Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. Cancer Research and Treatment, 2017, 49, 20-28.	1.3	34
88	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer, 2017, 17, 829.	1.1	77
89	High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low "Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. Clinical Oncology, 2016, 28, e173-e178.	0.6	33
90	Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. Radiation Oncology, 2016, 11, 76.	1.2	59

#	ARTICLE	IF	CITATIONS
91	Outcome Evaluation of Patients With Diagnosed WHO Grade III Glioma Treated According to the Molecular Profile, the Histology, and the Extent of Resection (EOR). International Journal of Radiation Oncology Biology Physics, 2016, 96, E109.	0.4	0
92	Role of Stereotactic Body Radiation Therapy With Volumetric Modulated Arc Therapy Technique and FFF Beams for Abdomino-Pelvic Lymph Node Metastases in Oligometastatic Patients. International Journal of Radiation Oncology Biology Physics, 2016, 96, E142-E143.	0.4	0
93	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. Cancer Treatment Reviews, 2016, 50, 1-8.	3.4	30
94	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. Cancer Investigation, 2016, 34, 348-354.	0.6	16
95	EP-1442: Oligometastatic colorectal cancer in elderly patients: role of stereotactic body radiation therapy. Radiotherapy and Oncology, 2016, 119, S669-S670.	0.3	0
96	PV-0511: Hypofractionated VMAT for early stage breast cancer: acute toxicity and cosmesis in 840 patients. Radiotherapy and Oncology, 2016, 119, S241-S242.	0.3	0
97	EP-1279: SABR in inoperable liver oligometastatic patients and radioresistant primary tumors.. Radiotherapy and Oncology, 2016, 119, S601-S602.	0.3	0
98	Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy. BMC Cancer, 2016, 16, 362.	1.1	18
99	Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. Oncotarget, 2016, 7, 53321-53329.	0.8	13
100	Role of SBRT with VMAT technique and FFF beams for lymph-node metastases in oligometastatic patients from genitourinary malignancies.. Journal of Clinical Oncology, 2016, 34, e16136-e16136.	0.8	0
101	Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy. Radiation Oncology, 2015, 10, 224.	1.2	22
102	The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). Journal of Cancer Research and Clinical Oncology, 2015, 141, 1301-1309.	1.2	135
103	A PPAR-gamma agonist attenuates pulmonary injury induced by irradiation in a murine model. Lung Cancer, 2015, 90, 405-409.	0.9	21
104	Imaging biomarkers in primary brain tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 597-612.	3.3	23
105	Hypofractionated stereotactic radiation therapy in skull base meningiomas. Journal of Neuro-Oncology, 2015, 124, 283-289.	1.4	31
106	The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. British Journal of Radiology, 2015, 88, 20150111.	1.0	15
107	Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy. BMC Cancer, 2014, 14, 833.	1.1	19
108	Low Prevalence of K-RAS, EGF-R and BRAF Mutations in Sinonasal Adenocarcinomas. Implications for Anti-EGFR Treatments. Pathology and Oncology Research, 2014, 20, 571-579.	0.9	46

#	ARTICLE	IF	CITATIONS
109	Impact of a breathing-control system on target margins and normal-tissue sparing in the treatment of lung cancer: experience at the radiotherapy unit of Florence University. <i>Radiologia Medica</i> , 2014, 119, 13-19.	4.7	12
110	Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1937-1945.	1.2	3
111	Radiotherapy Timing in the Treatment of Limited-stage Small Cell Lung Cancer: The Impact of Thoracic and Brain Irradiation on Survival. <i>Tumori</i> , 2014, 100, 289-295.	0.6	5
112	Radiotherapy timing in the treatment of limited-stage small cell lung cancer: the impact of thoracic and brain irradiation on survival. <i>Tumori</i> , 2014, 100, 289-95.	0.6	3
113	Management of inflammatory breast cancer: Focus on radiotherapy with an evidence-based approach. <i>Cancer Treatment Reviews</i> , 2013, 39, 119-124.	3.4	16
114	Application of helical tomotherapy for the treatment of a right atrium angiosarcoma: a case report. <i>Tumori</i> , 2013, 99, e233-6.	0.6	2
115	Isolated Chest Wall Implantation of Non-Small Cell Lung Cancer after Fine-Needle Aspiration: A Case Report and Review of the Literature. <i>Tumori</i> , 2012, 98, e126-e129.	0.6	7
116	Limited-Stage Small-Cell Lung Cancer Treated with Early Chemo-Radiotherapy: The Impact of Effective Chemotherapy. <i>Tumori</i> , 2012, 98, 53-59.	0.6	3
117	Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. <i>Cancer</i> , 2012, 118, 3236-3243.	2.0	39
118	Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. <i>Journal of Neuro-Oncology</i> , 2012, 108, 291-308.	1.4	50
119	Limited-stage small-cell lung cancer treated with early chemo-radiotherapy: the impact of effective chemotherapy. <i>Tumori</i> , 2012, 98, 53-9.	0.6	1
120	Isolated chest wall implantation of non-small cell lung cancer after fine-needle aspiration: a case report and review of the literature. <i>Tumori</i> , 2012, 98, 126e-129e.	0.6	9
121	Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Chemotherapy</i> , 2011, 23, 36-39.	0.7	3
122	Pegylated Liposomal Doxorubicin (Caelyx [®]) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines. <i>Journal of Chemotherapy</i> , 2011, 23, 158-162.	0.7	3